SCHEDULE: Bank of America Discloses 4.1% Stake in Novavax

Bank of America Corporation has reported a 4.1% beneficial ownership in Novavax Inc. common stock as of March 31, 2026.

Summary

• Bank of America Corporation, through its subsidiaries, now beneficially owns 6,655,398 shares of Novavax Inc. common stock.
• This represents 4.1% of the class of securities.
• The filing is an amendment to a previous Schedule 13G filing.
• The beneficial ownership calculation is based on 162,935,945 outstanding shares of Novavax Inc. as disclosed in its Form 10-K filed on February 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of an existing or newly acquired significant stake by a major financial institution, without providing new operational or financial performance data for Novavax.

Positives

• Bank of America's reporting indicates a significant institutional holding in Novavax, which can be seen as a sign of confidence by a major financial institution.

Risks

• The filing does not explicitly mention any risks associated with this ownership stake.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. Bank of America's reporting of a 4.1% stake in Novavax is a standard regulatory action and does not inherently signal a change in investment strategy or outlook for Novavax, but it does confirm a substantial institutional presence.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding by Bank of America, which may be viewed positively by some investors as a sign of institutional support or interest.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Novavax, Bank of America, Schedule 13G, beneficial ownership, institutional holding, common stock, SEC filing